The DOI matches its Crossref record; 276 of the 276 references it cites were found in a registry or an index.
Delivering safer immunotherapies for cancer
Open accessAbstract
Cancer immunotherapy is now a powerful clinical reality, with a steady progression of new drug approvals and a massive pipeline of additional treatments in clinical and preclinical development. However, modulation of the immune system can be a double-edged sword: Drugs that activate immune effectors are prone to serious non-specific systemic inflammation and autoimmune side effects. Drug delivery technologies have an important role to play in harnessing the power of immune therapeutics while avoiding on-target/off-tumor toxicities. Here we review mechanisms of toxicity for clinically-relevant immunotherapeutics, and discuss approaches based in drug delivery technology to enhance the safety and potency of these treatments. These include strategies to merge drug delivery with adoptive cellular therapies, targeting immunotherapies to tumors or select immune cells, and localizing therapeutics intratumorally. Rational design employing lessons learned from the drug delivery and nanomedicine fields has the potential to facilitate immunotherapy reaching its full potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–276 of 276
Liposomal cancer therapy: exploiting tumor characteristics
Kaasgaard, T., & Andresen, T. L. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903427940 · Cited by 122
Dubrot, J., Milheiro, F., Alfaro, C., Palazón, A., Martínez‐Forero, I., Perez‐Gracia, J. L., Morales‐Kastresana, A., Romero-Trevejo, J. L., Ochoa, M. C., Hervás‐Stubbs, S., et al. (2010) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-010-0846-9 · Cited by 115
Farolfi, A., Melegari, E., Aquilina, M., Scarpi, E., Ibrahim, T., Maltoni, R., Sarti, S., Cecconetto, L., Pietri, E., Ferrario, C., et al. (2013) · Heart · doi:10.1136/heartjnl-2012-303151 · Cited by 112
Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure‐Kunkel, M., Teitz‐Tennenbaum, S., & Chang, A. E. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0590 · Cited by 111
Pradhan, P., Qin, H., Leleux, J. A., Gwak, D., Sakamaki, I., Kwak, L. W., & Roy, K. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.039 · Cited by 111
Drenkard, D., Becke, F. M., Langstein, J., Spruß, T., Kunz‐Schughart, L. A., Tan, T. E., Lim, Y. C., & Schwarz, H. (2006) · The FASEB Journal · doi:10.1096/fj.05-4739com · Cited by 110
Wilcox, R. A., Tamada, K., Flies, D. B., Zhu, G., Chapoval, A. I., Blazar, B. R., Kast, W. M., & Chen, L. (2003) · Blood · doi:10.1182/blood-2003-06-2184 · Cited by 108
Immunocytokines: a review of molecules in clinical development for cancer therapy
List, T., & Neri, D. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s49231 · Cited by 104
Turning tumors into vaccines: co-opting the innate immune system.
van den Boorn, J. G., & Hartmann, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.011 · Cited by 104
Weide, B., Eigentler, T., Pflugfelder, A., Zelba, H., Martens, A., Pawelec, G., Giovannoni, L., Ruffini, P. A., Elia, G., Neri, D., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0206 · Cited by 100
Aronson, F. R., Libby, P., Brandon, E. P., et al. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.1.158 · Cited by 99
In VivoTargeting of Intratumor Regulatory T Cells Using PEG-Modified Single-Walled Carbon Nanotubes
Sacchetti, C., Rapini, N., Magrini, A., Cirelli, E., Stefano Bellucci, A., Mattei, M., Rosato, N., Bottini, N., & Bottini, M. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400070q · Cited by 98
Schrand, B., Berezhnoy, A., Brenneman, R., Williams, A. J., Levay, A. K., Kong, L.-Y., Rao, G., Zhou, S., Heimberger, A. B., & Gilboa, E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0007 · Cited by 98
Liu, J., Blake, S. J., Harjunpää, H., Fairfax, K. A., Yong, M. C. R., Allen, S. M., Kohrt, H. E. K., Takeda, K., Smyth, M. J., & Teng, M. W. L. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0194 · Cited by 95
Hanes, J. S., Sills, A. K., Zhao, Z., Suh, K., Tyler, B., DiMeco, F., Brat, D. J., Choti, M. A., Leong, K. W., Pardoll, D. M., et al. (2001) · Pharmaceutical Research · doi:10.1023/a:1010963307097 · Cited by 94
Suschek, C. V., Rothe, H. M., Fehsel, K., Enczmann, J., & Kolb-Bachofen, V. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.6.3283 · Cited by 91
Becker, J. C., Pancook, J. D., Gillies, S. D., Mendelsohn, J. M., & Reisfeld, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2702 · Cited by 91
Wayteck, L., Dewitte, H., Backer, L. D., Breckpot, K., Demeester, J., Smedt, S. C. D., & Raemdonck, K. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.11.016 · Cited by 91
van Herpen, C. M. L., van der Voort, R., van der Laak, J. A. W. M., Klasen, I. S., de Graaf, A. O., van Kempen, L. C. L. T., de Vries, I. J. M., Boer, T. D., Dolstra, H., Torensma, R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23756 · Cited by 90
Adoptive T‐cell therapy: adverse events and safety switches
Tey, S. (2014) · Clinical & Translational Immunology · doi:10.1038/cti.2014.11 · Cited by 88
Rationale for anti-CD137 cancer immunotherapy
Makkouk, A., Chester, C., & Kohrt, H. E. K. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.09.026 · Cited by 84
Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic Antibodies
Waibler, Z., Sender, L. Y., Merten, C., Hartig, R., Kliche, S., Gunzer, M., Reichardt, P., Kalinke, U., & Schraven, B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001708 · Cited by 79
Regulatory T cells in the prevention of mucosal inflammatory diseases: Patrolling the border
Lan, R. Y., Mackay, I. R., & Gershwin, M. E. (2007) · Journal of Autoimmunity · doi:10.1016/j.jaut.2007.07.021 · Cited by 79
Cytokine Conditioning Enhances Systemic Delivery and Therapy of an Oncolytic Virus
Ilett, E. J., Kottke, T. J., Donnelly, O., Thompson, J., Willmon, C. L., Díaz, R. M., Zaidi, S., Coffey, M. C., Selby, P. J., Harrington, K. J., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.118 · Cited by 75
Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy
Eisenstein, S. G., Coakley, B. A., Briley-Saebo, K. C., Ma, G., Chen, H.-M., Meseck, M. L., Ward, S., Divino, C. M., Woo, S. L. C., Chen, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1597 · Cited by 75
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy
Hori, Y., Stern, P., Hynes, R. O., & Irvine, D. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.037 · Cited by 70
Self-citationJeanbart, L., Kourtis, I. C., van der Vlies, A. J., Swartz, M. A., & Hubbell, J. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1702-8 · Cited by 68
Phase I study of intratumoral application of recombinant human tumor necrosis factor
Pfreundschuh, M. G., Steinmetz, H. T., Tüschen, R., Schenk, V., Diehl, V., & Schaadt, M. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90034-5 · Cited by 66
Burga, R. A., Patel, S., Bollard, C. M., Cruz, C. C., & Fernandes, R. (2016) · Nanomedicine · doi:10.2217/nnm-2016-0160 · Cited by 65
Bartsch, H. H., Pfizenmaier, K., Schroeder, M. P., & Nagel, G. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90021-7 · Cited by 64
CD28 Superagonists: What Makes the Difference in Humans?
Schraven, B. L., & Kalinke, U. (2008) · Immunity · doi:10.1016/j.immuni.2008.04.003 · Cited by 63
Egilmez, N. K., Jong, Y. S., Iwanuma, Y., Jacob, J. S., Santos, C. A., Chen, F.-A., Mathiowitz, E., & Bankert, R. B. (1998) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050455 · Cited by 62
Orucevic, A., & Lala, P. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.34 · Cited by 62
Morris, N. P., Peters, C., Montler, R. D., Hu, H., Curti, B. D., Urba, W. J., & Weinberg, A. D. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.02.004 · Cited by 61
Effective Melanoma Immunotherapy with Interleukin-2 Delivered by a Novel Polymeric Nanoparticle
Yao, H., Ng, S. S., Huo, L.-F., Chow, B., Shen, Z., Yang, M., Sze, J., Ko, O. K. H., Li, M., Yue, A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0717 · Cited by 61
Alwan, L. M., Grossmann, K. F., Sageser, D. S., Atta, J. V., Agarwal, N., & Gilreath, J. A. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0276-7 · Cited by 60
T-cell therapy at the threshold
June, C. H., Rosenberg, S. A., Sadelain, M., & Weber, J. S. (2012) · Nature Biotechnology · doi:10.1038/nbt.2305 · Cited by 59
Kim, Y. H., Choi, B. K., Kim, K. H., Kang, S. W., & Kwon, B. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1365 · Cited by 59
A New VISTA on combination therapy for negative checkpoint regulator blockade
Deng, J., Mercier, I. L., Kuta, A., & Noelle, R. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0190-5 · Cited by 57
Giragossian, C., Clark, T. H., Piche‐Nicholas, N., & Bowman, C. (2013) · Current Drug Metabolism · doi:10.2174/13892002113149990099 · Cited by 55
CD137 on inflamed lymphatic endothelial cells enhances CCL21‐guided migration of dendritic cells
Teijeira, Á., Palazón, A., Garasa, S., Marré, D., Aubá, C., Rogel, A., Murillo, O., Martínez‐Forero, I., Lang, F., Melero, I., et al. (2012) · The FASEB Journal · doi:10.1096/fj.11-201061 · Cited by 53
Interleukin-2 Functionalized Nanocapsules for T Cell-Based Immunotherapy
Frick, S. U., Domogalla, M. P., Baier, G., Wurm, F. R., Mailänder, V., Landfester, K., & Steinbrink, K. (2016) · ACS Nano · doi:10.1021/acsnano.5b07973 · Cited by 53
Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Smolkin, M. E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Chianese‐Bullock, K. A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1881-y · Cited by 51
Puskas, J., Skrombolas, D., Sedlacek, A. L., Lord, E. M., Sullivan, M. A., & Frelinger, J. G. (2011) · Immunology · doi:10.1111/j.1365-2567.2011.03428.x · Cited by 50
Narazaki, H., Zhu, Y., Luo, L., Zhu, G., & Chen, L. (2010) · Blood · doi:10.1182/blood-2008-12-192591 · Cited by 50
Toxicities Associated With Adoptive T-Cell Transfer for Cancer
Yang, J. C.-H. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000157 · Cited by 50
Kramer, M. G., Masner, M., Casales, E., Moreno, M., Smerdou, C., & Chabalgoity, J. A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1618-x · Cited by 49
Neoadjuvant immunotherapy with chitosan and interleukin-12 to control breast cancer metastasis
Vo, J., Yang, L., Kurtz, S. L., Smith, S. G., Koppolu, B., Ravindranathan, S., & Zaharoff, D. A. (2014) · OncoImmunology · doi:10.4161/21624011.2014.968001 · Cited by 49
Response to 'Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial'
Hünig, T. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c2 · Cited by 48
Aglycosylated Chimeric Mouse/Human IgG1 Antibody Retains Some Effector Function
Dorai, H., Mueller, B. M., Reisfeld, R. A., & Gillies, S. D. (1991) · Hybridoma · doi:10.1089/hyb.1991.10.211 · Cited by 48
Smith, S. G., Koppolu, B., Ravindranathan, S., Kurtz, S. L., Yang, L., Katz, M. D., & Zaharoff, D. A. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1672-x · Cited by 48
Tyrsin, D., Chuvpilo, S. A., Matskevich, A. A., Nemenov, D., Römer, P. S., Tabares, P., & Hünig, T. (2016) · PubMed · Cited by 47
A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats
Müller, N., van den Brandt, J., Odoardi, F., Tischner, D., Herath, J., Flügel, A., & Reichardt, H. M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32698 · Cited by 46
Temporally Programmed CD8α+ DC Activation Enhances Combination Cancer Immunotherapy
Tzeng, A., Kauke, M. J., Zhu, E. F., Moynihan, K. D., Opel, C. F., Yang, N. J., Mehta, N. K., Kelly, R. L., Szeto, G. L., Overwijk, W. W., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.11.020 · Cited by 46
Self-citationLin, G. H. Y., Liu, Y., Ambagala, T., Kwon, B. S., Ohashi, P. S., & Watts, T. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011003 · Cited by 44
Yu, M., Lam, J., Rada, B., Leto, T. L., & Levine, S. J. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001499 · Cited by 44
Buchbinder, E. I., Gunturi, A., Perritt, J. C., Dutcher, J. P., Aung, S., Kaufman, H. L., Ernstoff, M. S., Miletello, G. P., Curti, B. D., Daniels, G. A., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0155-8 · Cited by 44
Gubbels, J. A. A., Gadbaw, B., Buhtoiarov, I. N., Horibata, S., Kapur, A., Patel, D., Hank, J. A., Gillies, S. D., Sondel, P. M., Patankar, M. S., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1072-9 · Cited by 40
Guiducci, C., Carlo, E. D., Parenza, M., Hitt, M., Giovarelli, M., Musiani, P., & Colombo, M. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4026 · Cited by 38
Current and Potential Uses of Immunocytokines as Cancer Immunotherapy
Sondel, P. M., & Gillies, S. D. (2012) · Antibodies · doi:10.3390/antib1020149 · Cited by 38
Buhtoiarov, I. N., Neal, Z. C., Gan, J., et al. (2011) · Journal of Leukocyte Biology · doi:10.1189/jlb.0710422 · Cited by 38
Shir, A., Ogris, M., Röedl, W., Wagner, E., & Levitzki, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1140 · Cited by 37
Antigen-specific T cell Redirectors: a nanoparticle based approach for redirecting T cells
Schütz, C., Varela, J. C., Perica, K., Haupt, C., Oelke, M., & Schneck, J. P. (2016) · Oncotarget · doi:10.18632/oncotarget.11785 · Cited by 34
Intratumoral immunotherapy for melanoma
Singh, M., & Overwijk, W. W. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1727-z · Cited by 33
Complement C3 mediated targeting of liposomes to granulocytic myeloid derived suppressor cells
Kullberg, M., Martinson, H. A., Mann, K., & Anchordoquy, T. J. (2015) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2015.03.010 · Cited by 32
Regulating Cytokine Function Enhances Safety and Activity of Genetic Cancer Therapies
Chen, H., Sampath, P., Hou, W., & Thorne, S. H. (2013) · Molecular Therapy · doi:10.1038/mt.2012.225 · Cited by 30
Posch, C., Weihsengruber, F., Bartsch, K., Feichtenschlager, V., Sanlorenzo, M., Vujic, I., Itzinger-Monshi, B., Ortiz‐Urda, S., & Rappersberger, K. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.62 · Cited by 30
Iyer, S. S., & Amara, R. R. (2014) · Vaccines · doi:10.3390/vaccines2010160 · Cited by 29
Induction of antitumor immunity via intratumoral tetra-costimulator protein transfer.
Zheng, G., Chen, A., Sterner, R. E., Zhang, P. J., Pan, T., Kiyatkin, N., & Tykocinski, M. L. (2001) · PubMed · Cited by 28
Intratumoral delivery of CpG-conjugated anti-MUC1 antibody enhances NK cell anti-tumor activity
Schettini, J. L., Kidiyoor, A., Besmer, D. M., Tinder, T. L., Roy, L. D., Lustgarten, J., Gendler, S. J., & Mukherjee, P. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1264-y · Cited by 27
Large‐scale expansion of rat CD4+ CD25+ Treg cells in the absence of T‐cell receptor stimulation
Beyersdorf, N., Balbach, K., Hünig, T., & Kerkau, T. (2006) · Immunology · doi:10.1111/j.1365-2567.2006.02455.x · Cited by 26
Therapeutic efficacy of the F8-IL2 immunocytokine in a metastatic mouse model of lung adenocarcinoma
Wieckowski, S., Hemmerle, T., Prince, S. S., Schlienger, B. D., Hillinger, S., Neri, D., & Zippelius, A. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.019 · Cited by 24
Liu, S., Breiter, D. R., Zheng, G., & Chen, A. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3301 · Cited by 18
Sester, U., Wabnitz, G. H., Kirchgessner, H., & Samstag, Y. (2007) · European Journal of Immunology · doi:10.1002/eji.200737206 · Cited by 12
Stevens, P. R., & Piazza, D. (1990) · International Journal of Immunopharmacology · doi:10.1016/0192-0561(90)90097-7 · Cited by 12
Cruz, L. J., Rueda, F., Tacken, P. J., Alberício, F., Torensma, R., & Figdor, C. G. (2012) · Nanomedicine · doi:10.2217/nnm.12.131 · Cited by 6
Cited by
Delivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Therapeutic Targeting of the Tumor Microenvironment
Bejarano, L., Jordāo, M. J. C., & Joyce, J. A. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1808 · Cited by 1,653
Breast cancer: Biology, biomarkers, and treatments
Barzaman, K., Karami, J., Zarei, Z., Hosseinzadeh, A., Kazemi, M. H., Moradi-Kalbolandi, S., Safari, E., & Farahmand, L. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106535 · Cited by 973
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Carter, P. J., & Lazar, G. A. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 754
Metadata
- Authors
- Milling, L., Zhang, Y., & Irvine, D. J.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-05
- Volume
- 114
- Pages
- 79-101
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2617871758
- Cited by
- 305
- References
- 276
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.